Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 1

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 1
---
 125,000,000
    shares authorized; 33,103,860 issued and
    outstanding, respectively 
     3,310  
     3,310 
  
    Additional paid in capital 
     30,612,281  
     30,190,827 
  
    Accumulated deficit 
     (27,550,996) 
     (26,022,129)
  
    Total stockholders’ equity 
     3,064,595  
     4,172,008 
  
    Total liabilities and stockholders’ equity 
    $4,962,826  
    $6,202,409 

The accompanying notes are an integral part of
these condensed consolidated financial statements

5

JUPITER NEUROSCIENCES, INC.

 CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

    Three Months Ended 

    March 31, 2025   
    March 31, 2024  

    Expenses: 

    Research and development 
    $466,745  
    $98,667 
  
    General and administrative 
     1,071,258  
     472,028 
  
    Total operating expenses 
     1,538,003  
     570,695 

    Loss from operations 
     (1,538,003) 
     (570,695)

    Other Income (Expenses): 

    Interest income 
     10,365  
     62 
  
    Loss on change in fair value of derivative liability 
     -  
     (37,711)
  
    Interest expense 
     (1,229) 
     (65,756)
  
    Other income 
     -  
     40,000 
  
    Total other income (expenses), net 
     9,136  
     (63,405)

    Net loss 
    $(1,528,867) 
    $(634,100)

    Net loss per common share: 

    Basic and diluted 
    $(0.05) 
    $(0.02)

    Weighted average number of common stock outstanding: 

    Basic and diluted 
     33,103,860  
     26,526,405 

The accompanying notes are an integral part of these
condensed consolidated financial statements

6

JUPITER NEU